Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s616713 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Weihong Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Nanoparticles, Janus Kinase 2, Janus Kinase 1. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Although inhibition of the JAK-STAT signaling pathway has shown promise in cancer therapy, the therapeutic potential of PROTAC-mediated JAK1/JAK2 degradation in bladder cancer remains to be fully explored. To improve the delivery and therapeutic efficacy of PROTAC-mediated JAK1/JAK2 degradation in bladder cancer, this study developed PPcJ, a cRGD-functionalized PLGA-PEG nanoparticle encapsulating the PROTAC-based JAK1/JAK2 degrader JAPT8.
Methods
PPcJ nanoparticles were characterized using transmission electron microscopy, dynamic light scattering, and high-performance liquid chromatography. Flow cytometry and confocal microscopy were used to evaluate cytotoxicity, anti-tumor effect, and intracellular localization, while Western blotting assessed the expression of JAK/STAT pathway and apoptosis-related proteins. In vivo tumor-associated fluorescence, antitumor efficacy, survival, histopathology, and serum biochemical parameters were assessed in tumor-bearing mice.
Results
PPcJ exhibited a spherical nanoscale morphology. PPcJ achieved near-plateau cellular uptake at low concentrations and partially evaded lysosomal degradation, which significantly induced apoptosis in bladder cancer cells and suppressed key components of the JAK/STAT signaling pathway. In vivo, cRGD modification enabled higher tumor-specific accumulation and prolonged retention. PPcJ inhibited tumor growth by 86.2% and prolonged mean survival from 22.4 ± 4.2 to 41.0 ± 2.2 days, without significant changes in body weight, major-organ histology, or serum AST, ALT, urea, and creatinine levels under the tested conditions.
Conclusion
These findings provide a preclinical proof-of-concept that the PPcJ nano-delivery system improves the delivery and antitumor performance of JAPT8. This strategy warrants further evaluation in systemic therapeutic approaches for bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China.
- Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, People's Republic of China.
ORCID-Profile: Weihong Ding, Zongguang Tai
Zitieren
APA
Ding, W., Zhang, X., Wu, H., Zhou, C., Xu, K., Tai, Z., & Xia, G. (2026). Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s616713
Vancouver
Ding W, Zhang X, Wu H, Zhou C, Xu K, Tai Z, et al. Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s616713
BibTeX
@article{Ding2026,
author = {Ding, Weihong and Zhang, Xinyue and Wu, Hongdan and Zhou, Congrui and Xu, Ke and Tai, Zongguang and Xia, Guowei},
title = {Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s616713}
}
EUVIMED